

In the Claims:

Please amend the claims as follows:

1 (currently amended). A method of screening a subject for [a] increased risk of proliferative disease [risk factor], comprising:
detecting the presence or absence of upregulation of the *CLN3* gene in said subject;
the upregulation of the *CLN3* gene in said subject indicating said subject is at increased risk of developing a proliferative disease;
said proliferative disease selected from the group consisting of breast cancer, melanoma, lung cancer, colon cancer leukemia, soft tissue and bone sarcomas, neuroendocrine tumors, squamous carcinomas, and adenocarcinomas.

2 (original). The method of claim 1, wherein said subject has been previously diagnosed as afflicted with said proliferative disease.

3 (original). The method of claim 1, wherein said subject has not been previously diagnosed as afflicted with said proliferative disease.

4 (original). The method of claim 1, wherein said subject has been previously prognosed to be at risk of developing said proliferative disease.

5 (original). The method of claim 1, wherein said subject has not been previously prognosed to be at risk of developing said proliferative disease.

6 (original). The method of claim 1, wherein said detecting step is carried out by detecting increased mRNA levels for said *CLN3* gene.

7 (cancelled).

In re: Boustany et al.
Serial No.: 09/830,045
Filed: April 20, 2002
Page 5

8 (original). The method of claim 1, wherein said proliferative disease is breast cancer.

9 (original). The method of claim 1, wherein said proliferative disease is colon cancer.

10 (currently amended). A method according to claim 1, wherein said [patient] subject has undergone treatment for said proliferative disease.

11-46 (cancelled).